2,390
Views
6
CrossRef citations to date
0
Altmetric
Article

Assessment of antifungal efficacy of itraconazole loaded aspasomal cream: comparative clinical study

, , , ORCID Icon &
Pages 1345-1357 | Received 28 Feb 2022, Accepted 11 Apr 2022, Published online: 04 May 2022

References

  • Aboul-Einien MH, Kandil SM, Abdou EM, et al. (2020). Ascorbic acid derivative-loaded modified aspasomes: formulation, in vitro, ex vivo and clinical evaluation for melasma treatment. J Liposome Res 30:54–67.
  • Al-Suwayeh SA, Taha EI, Al-Qahtani FM, et al. (2014). Evaluation of skin permeation and analgesic activity effects of carbopol lornoxicam topical gels containing penetration enhancer. Sci World J 2014:1–9.
  • Aly R, Berger T. (1996). Common superficial fungal infections in patients with AIDS. Clin Infect Dis 22:S128–S32.
  • Amer SS, Nasr M, Abdel-Aziz RT, et al. (2020). Cosm-nutraceutical nanovesicles for acne treatment: physicochemical characterization and exploratory clinical experimentation. Int J Pharm 577:119092.
  • Bhat YJ, Keen A, Hassan I, et al. (2019). Can dermoscopy serve as a diagnostic tool in dermatophytosis? A pilot study. Indian Dermatol Online J 10:530–5.
  • Bishnoi A, Handa S, Vinay K. (2018). “Over the Internet” sale of prescription-level topical corticosteroids and dilemma of dermatologists. Int J Dermatol 57:1403–7.
  • Bourlond A, Lachapelle JM, Aussems J, et al. (1989). Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol 28:410–2.
  • Bseiso E, Nasr M, Sammour O, Abd El Gawad N. (2015). Recent advances in topical formulation carriers of antifungal agents. Indian J Dermatol Venereol Leprol 81:457–63.
  • Chen SC, Sorrell TC. (2007). Antifungal agents. Med J Aust 187:404–9.
  • Dadar M, Tiwari R, Karthik K, et al. (2018). Candida albicans—biology, molecular characterization, pathogenicity, and advances in diagnosis and control – an update. Microb Pathog 117:128–38.
  • Degreef H, Marien K, De Veylder H, et al. (1987). Itraconazole in the treatment of dermatophytoses: a comparison of two daily dosages. Rev Infect Dis 9:S104–S8.
  • Doğan İS, Sarac S, Sari S, et al. (2017). New azole derivatives showing antimicrobial effects and their mechanism of antifungal activity by molecular modeling studies. Eur J Med Chem 130:124–38.
  • Drake LA, Dinehart SM, Farmer ER, et al. (1996). Guidelines of care for superficial mycotic infections of the skin: tinea capitis and tinea barbae. J Am Acad Dermatol 34:290–4.
  • El-Gizawy SA, Nouh A, Saber S, Kira AY. (2020). Deferoxamine-loaded transfersomes accelerates healing of pressure ulcers in streptozotocin-induced diabetic rats. J Drug Deliv Sci Technol 58:101732.
  • El-Sheridy NA, Ramadan AA, Eid AA, El-Khordagui LK. (2019). Itraconazole lipid nanocapsules gel for dermatological applications: in vitro characteristics and treatment of induced cutaneous candidiasis. Colloids Surf B Biointerfaces 181:623–31.
  • Estrada RA. (1987). Itraconazole in pityriasis versicolor. Rev Infect Dis 9:S128–S30.
  • Fluhr JW, Darlenski R, Surber CJBJ. (2008). Glycerol and the skin: holistic approach to its origin and functions. Br J Dermatol 159:23–34.
  • Garg T, Rath G, Goyal AK. (2015). Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv 22:969–87.
  • Ghosh S, Mukherjee B, Chaudhuri S, et al. (2018). Methotrexate aspasomes against rheumatoid arthritis: optimized hydrogel loaded liposomal formulation with in vivo evaluation in Wistar rats. AAPS PharmSciTech 19:1320–36.
  • Gopinath D, Ravi D, Rao BR, et al. (2004). Ascorbyl palmitate vesicles (aspasomes): formation, characterization, and applications. Int J Pharm 271:95–113.
  • Gupta AK, Chaudhry M, Elewski B. (2003). Tinea corporis, tinea cruris, tinea nigra, and piedra. Dermatol Clin 21:395–400.
  • Hatem S, Nasr M, Moftah NH, et al. (2018). Melatonin vitamin C-based nanovesicles for treatment of androgenic alopecia: design, characterization and clinical appraisal. Eur J Pharm Sci 122:246–53.
  • Hay RJ, Clayton YM. (1987). Treatment of chronic dermatophytosis and chronic oral candidosis with itraconazole. Rev Infect Dis 9:S114–S8.
  • Ho HN, Le TG, Dao TTT, et al. (2020). Development of itraconazole-loaded polymeric nanoparticle dermal gel for enhanced antifungal efficacy. J Nanomater 2020:1–11.
  • Jerajani HR, Amladi ST, Bongale R, et al. (2000). Evaluation of clinical efficacy and safety of once daily topical administration of 1% oxiconazole cream and lotion in dermatophytosis: an open label, non-comparative multicentre study. Indian J Dermatol Venereol Leprol 66:188–92.
  • Jukanti R, Devraj G, Shashank AS, Devraj R. (2011). Biodistribution of ascorbyl palmitate loaded doxorubicin pegylated liposomes in solid tumor bearing mice. J Microencapsul 28:142–9.
  • Kalavathy CM, Parmar P, Kaliamurthy J, et al. (2005). Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis. Cornea 24:449–52.
  • Kaur IP, Kakkar S. (2010). Topical delivery of antifungal agents. Expert Opin Drug Deliv 7:1303–27.
  • Khalil RM, Abdelbary A, Arini SKE, et al. (2021). Development of tizanidine loaded aspasomes as transdermal delivery system: ex-vivo and in-vivo evaluation. J Liposome Res 31:19–29.
  • Khurana A, Agarwal A, Singh A, et al. (2021). Predicting a therapeutic cut-off serum level of itraconazole in recalcitrant tinea corporis and cruris—a prospective trial. Mycoses 64:1480–8.
  • Kianvash N, Bahador A, Pourhajibagher M, et al. (2017). Evaluation of propylene glycol nanoliposomes containing curcumin on burn wound model in rat: biocompatibility, wound healing, and anti-bacterial effects. Drug Deliv Transl Res 7:654–63.
  • Korting HC, Klövekorn W, Klövekorn G. (1997). Comparative efficacy and tolerability of econazole liposomal gel 1%, branded econazole conventional cream 1% and generic clotrimazole cream 1% in tinea pedis. Clin Drug Invest 14:286–93.
  • Kumar N, Goindi S. (2014). Statistically designed nonionic surfactant vesicles for dermal delivery of itraconazole: characterization and in vivo evaluation using a standardized tinea pedis infection model. Int J Pharm 472:224–40.
  • Kumar N, Goindi S. (2021). Development and optimization of itraconazole-loaded solid lipid nanoparticles for topical administration using high shear homogenization process by design of experiments: in vitro, ex vivo and in vivo evaluation. AAPS PharmSciTech 22:1–21.
  • Kumar N, Goindi S. (2021). Development, characterization and preclinical evaluation of nanosized liposomes of itraconazole for topical application: 32 full factorial design to estimate the relationship between formulation components. J Drug Deliv Sci Technol 66:102785.
  • Lamie C, Elmowafy E, Attia DA, et al. (2022). Diversifying the skin cancer-fighting worthwhile frontiers: how relevant is the itraconazole/ascorbyl palmitate nanovectors? Nanomed Nanotechnol Biol Med 102561.
  • Ling X, Huang Z, Wang J, et al. (2016). Development of an itraconazole encapsulated polymeric nanoparticle platform for effective antifungal therapy. J Mater Chem B 4:1787–96.
  • Martin MV. (1999). The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review. J Antimicrob Chemother 44:429–37.
  • Matangi SP, Mamidi SA, Raghavamma STV, Nadendla RR. (2014). Formulation and evaluation of anti aging poly herbal cream. Skin 5:133–6.
  • Mathur M, Acharya P, Karki A, et al. (2019). Dermoscopic pattern of pityriasis versicolor. Clin Cosmet Investig Dermatol 12:303–9.
  • McNeely W, Spencer CM. (1998). Butenafine. Drugs 55:405–12.
  • Mendez-Tovar LJ. (2010). Pathogenesis of dermatophytosis and tinea versicolor. Clin Dermatol 28:185–9.
  • Mohamed AS, Fahmy SR, Elsayed AA. (2020). Formulation and evaluation of the sea cucumber, Holothuria arenicola extract incorporated skin cream. GSC Biol Pharm Sci 13:232–9.
  • Moribe K, Limwikrant W, Higashi K, Yamamoto K. (2011). Drug nanoparticle formulation using ascorbic acid derivatives. J Drug Deliv 2011:138929.
  • Nair A, Jacob S, Al-Dhubiab B, et al. (2013). Basic considerations in the dermatokinetics of topical formulations. Braz J Pharm Sci 49:423–34.
  • Ngatu NR, Saruta T, Hirota R, et al. (2011). Antifungal efficacy of Brazilian green propolis extracts and honey on tinea capitis and tinea versicolor. Eur J Integr Med 3:e281–e7.
  • Nucci M, Marr KA. (2005). Emerging fungal diseases. Clin Infect Dis 41:521–6.
  • Nuijten STM, Schuller JL. (1987). Itraconazole in the treatment of tinea corporis: a pilot study. Rev Infect Dis 9:S119–S20.
  • Odeniyi MA, Okumah VC, Adebayo-Tayo BC, Odeniyi OA. (2020). Green synthesis and cream formulations of silver nanoparticles of Nauclea latifolia (African peach) fruit extracts and evaluation of antimicrobial and antioxidant activities. Sustain Chem Pharm 15:100197.
  • Ozturk P, Arican O, Kurutas EB, et al. (2013). Local oxidative stress in interdigital tinea pedis. J Dermatol 40:114–7.
  • Passos JS, de Martino LC, Dartora VFC, et al. (2020). Development, skin targeting and antifungal efficacy of topical lipid nanoparticles containing itraconazole. Eur J Pharm Sci 149:105296.
  • Pedrosa AF, Lisboa C, Rodrigues AG. (2014). Malassezia infections: a medical conundrum. J Am Acad Dermatol 71:170–6.
  • Permana AD, Paredes AJ, Volpe-Zanutto F, et al. (2020). Dissolving microneedle-mediated dermal delivery of itraconazole nanocrystals for improved treatment of cutaneous candidiasis. Eur J Pharm Biopharm 154:50–61.
  • Permana AD, Utomo E, Pratama MR, et al. (2021). Bioadhesive-thermosensitive in situ vaginal gel of the gel flake-solid dispersion of itraconazole for enhanced antifungal activity in the treatment of vaginal candidiasis. ACS Appl Mater Interfaces 13:18128–41.
  • Qumber M, Alruwaili NK, Bukhari SNA, et al. (2021). BBD-based development of itraconazole loaded nanostructured lipid carrier for topical delivery: in vitro evaluation and antimicrobial assessment. J Pharm Innov 16:85–98.
  • Rapalli VK, Kaul V, Waghule T, et al. (2020). Curcumin loaded nanostructured lipid carriers for enhanced skin retained topical delivery: optimization, scale-up, in-vitro characterization and assessment of ex-vivo skin deposition. Eur J Pharm Sci 152:105438.
  • Rebora A, Marples RR, Kligman AM. (1973). Experimental infection with Candida albicans. Arch Dermatol 108:69–73.
  • Rezabek GH, Friedman AD. (1992). Superficial fungal infections of the skin. Diagnosis and current treatment recommendations. Drugs 43:674–82.
  • Ruocco E, Baroni A, Donnarumma G, Ruocco V. (2011). Diagnostic procedures in dermatology. Clin Dermatol 29:548–56.
  • Sardana K, Khurana A, Singh A. (2020). Scientific rationale of antifungal drug combination, including oral itraconazole and terbinafine, in recalcitrant dermatophytoses. J Dermatol Treatment 31:43–5.
  • Shah MKA, Azad AK, Nawaz A, et al. (2021). Formulation development, characterization and antifungal evaluation of chitosan NPs for topical delivery of voriconazole in vitro and ex vivo. Polymers 14:135.
  • Shinde G, Desai P, Shelke S, et al. (2022). Mometasone furoate-loaded aspasomal gel for topical treatment of psoriasis: formulation, optimization, in vitro and in vivo performance. J Dermatol Treatment 33:885–96.
  • Spraker MK, Gisoldi EM, Siegfried EC, et al. (2006). Topical miconazole nitrate ointment in the treatment of diaper dermatitis complicated by candidiasis. Cutis 77:113.
  • Subedi L, Song SY, Jha SK, et al. (2021). Preparation of topical itraconazole with enhanced skin/nail permeability and in vivo antifungal efficacy against superficial mycosis. Pharmaceutics 13:622.
  • Van Hecke E, Van Cutsem J. (1988). Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea pedis and tinea manuum. Mycoses 31:641–9.
  • Verma S, Utreja P. (2019). Vesicular nanocarrier based treatment of skin fungal infections: potential and emerging trends in nanoscale pharmacotherapy. Asian J Pharm Sci 14:117–29.
  • Verma S. (2007). Superficial fungal infection: dermatophytosis, onychomycosis, tinea nigra, piedra. Fitzpatrick's Dermatol Gen Med 2:1807–21.
  • Willems L, Van der Geest R, De Beule K. (2001). Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 26:159–69.
  • Zariwala MG, Farnaud S, Merchant Z, et al. (2014). Ascorbyl palmitate/DSPE-PEG nanocarriers for oral iron delivery: preparation, characterisation and in vitro evaluation. Colloids Surf B 115:86–92.
  • Zhang S, Song W, Wu H, et al. (2020). Lecithins-zein nanoparticles for antifungal treatment: enhancement and prolongation of drug retention in skin with reduced toxicity. Int J Pharm 590:119894.